AbbVie-Cerevel deal focused on antipsychotic drug hit with second request from US FTC
AbbVie’s proposed acquisition of Cerevel Therapeutics, which is focused on Cerevel's investigational treatment for schizophrenia and Alzheimer’s disease psychosis, received a second request from the US Federal Trade Commission. AbbVie already...To view the full article, register now.
Already a subscriber? Click here to view full article